It is all about execution now, TPIV is set for approximately two years with TPIV attracting $7,000,000 from both existing and new investors. Overall the existing investors are satisfied as well. TPIV has four Phase II trials underway with AstraZeneca, Memorial Sloan Kettering, MAYO and the DOD with two more company trials to begin soon. Throw in PolyStart for good measure. Additionally, Phase I results to be communicated and published very soon. Note Phase I results will be published by MAYO. Do you think MAYO would publish Phase I results if results were not positive? Do you think the above investors would invest in the company if Phase I results and ongoing progress of all Phase II trials were not positive? These investors are closest to the company with regards to potential of TPIV technology and applications. The new financing recognizes and validates the potential of TPIV. Further with new financing TPIV total cash position is in the range of $13 to $15 Million. Add the two trials with MAYO to be funded by the DOD of over $16 Million you have a total of approximately $30 Million in cash and cash commitments for a company with a current market cap of $33 Million. You are basicall getting the company for cash value. In summary, with above $30 Million cash position and good news coming within the next few weeks it is time to buy (not sell), it is time to establish new positions or add to existing holdings. TPIV looks like a real bargain and good news is coming soon. TPIV is going to $10 to $20/share in near future and who knows after that. Best of luck to all.
